The National Health Service (NHS) in England has launched a pioneering pilot program using a rapid DNA test to diagnose brain tumours in a matter of hours or days, significantly reducing the time patients typically wait for results. This genomic test examines DNA from biopsy or surgical samples to identify tumour types more quickly than conventional methods, which can take several weeks.

Traditional diagnostic approaches, including MRI and CT imaging combined with laboratory analysis of tumour tissue, often result in delays before a definitive diagnosis is confirmed. The new genomic testing method aims to accelerate this process, enabling patients to begin treatments such as radiotherapy or chemotherapy much sooner.

In addition to its use post-surgery, the test has been employed intraoperatively in cases where the tumour type is unclear. Surgeons have been able to receive results within approximately two hours during operations, assisting them in making more informed decisions about the extent of tumour removal.

The pilot scheme, initially conducted at specialist centres in Nottingham and Birmingham, is set to expand to five additional expert centres before being rolled out more widely across England. NHS medical director Professor Frankie Swords described the development as having the potential to "completely transform how we diagnose brain tumours."

One patient benefiting from the new testing is Steve Palmer, 55, from Nottingham, who was diagnosed with a grade 4 glioblastoma. Palmer emphasized the importance of the rapid diagnosis, stating that the prompt identification of the tumour type allowed for swift development of his treatment plan and alleviated weeks of uncertainty.

The accelerated diagnostic process offered by this genomic test represents a significant advancement in brain tumour care, promising earlier intervention and potentially improved outcomes for patients across the NHS.